Evaluating the prevalence of polyglutamine repeat expansions in amyotrophic lateral sclerosis

T. Lee, Y. R. Li, A. Chesi, M. P. Hart, D. Ramos, N. Jethava, D. Hosangadi, J. Epstein, B. Hodges, N. M. Bonini, A. D. Gitler

Research output: Contribution to journalArticle

Abstract

ObjectiveGiven the recent finding of an association between intermediate-length polyglutamine (polyQ) expansions in ataxin 2 and amyotrophic lateral sclerosis (ALS), we sought to determine whether expansions in other polyQ disease genes were associated with ALS. Methods: We assessed the polyQ lengths of ataxin 1, ataxin 3, ataxin 6, ataxin 7, TBP, atrophin 1, and huntingtin in several hundred patients with sporadic ALS and healthy controls. Results: Other than ataxin 2, we did not identify a significant association with the other polyQ genes and ALS. Conclusions: These data indicate that the effects of ataxin 2 polyQ expansions on ALS risk are likely to be rooted in the biology of ataxin 2 or ataxin 2-specific interactions, rather than the presence of an expanded polyQ repeat per se. These findings have important consequences for understanding the role of ataxin 2 in ALS pathogenesis and provide a framework for future mechanistic studies.

Original languageEnglish (US)
Pages (from-to)2062-2065
Number of pages4
JournalNeurology
Volume76
Issue number24
DOIs
StatePublished - Jun 14 2011

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Evaluating the prevalence of polyglutamine repeat expansions in amyotrophic lateral sclerosis'. Together they form a unique fingerprint.

  • Cite this

    Lee, T., Li, Y. R., Chesi, A., Hart, M. P., Ramos, D., Jethava, N., Hosangadi, D., Epstein, J., Hodges, B., Bonini, N. M., & Gitler, A. D. (2011). Evaluating the prevalence of polyglutamine repeat expansions in amyotrophic lateral sclerosis. Neurology, 76(24), 2062-2065. https://doi.org/10.1212/WNL.0b013e31821f4447